Branning Todd P. 4
4 · NeuBase Therapeutics, Inc. · Filed Nov 4, 2022
Insider Transaction Report
Form 4
Branning Todd P.
Chief Financial Officer
Transactions
- Award
Stock option (right to buy)
2022-11-03+200,000→ 200,000 totalExercise: $0.28Exp: 2032-11-03→ Common Stock (200,000 underlying)
Footnotes (1)
- [F1]50% of the total shares shall vest on March 1, 2023, and the remaining shares shall vest on November 1, 2023, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Shares are subject to accelerated vesting in the event of a change of control of the Issuer, provided that employment has not terminated prior to such vesting date, inclusive.